MyFinsight
Home
Blog
About
Net proceeds from
issuance of common stock...
$5,861,147
Purchases of property and
equipment
-$1
(-100.00%↓ Y/Y)
Net cash provided by
financing activities
$5,848,411
Net cash provided by
(used in) investing...
$1
(100.00%↑ Y/Y)
Canceled cashflow
$12,736
Net increase
(decrease) in cash, cash...
$4,208,134
(253.95%↑ Y/Y)
Canceled cashflow
$1,640,278
Payments on finance lease
obligations
$12,736
Stock-based compensation
$1,218,939
(37.81%↑ Y/Y)
Grants receivable
-$101,607
(78.83%↑ Y/Y)
Depreciation of property and
equipment
$76,949
(-46.10%↓ Y/Y)
Prepaid expenses and
other current assets
-$46,318
(39.35%↑ Y/Y)
Accounts payable and
accrued expenses
$40,146
(529.54%↑ Y/Y)
Net cash (used in)
operating activities
-$1,640,278
(38.60%↑ Y/Y)
Canceled cashflow
$1,483,959
Net loss
-$2,878,614
(31.73%↑ Y/Y)
Change in fair value of
derivative instruments
$172,859
Non-cash lease expense
-$28,751
(-296.53%↓ Y/Y)
Due from related
party
-$18,616
Due to related party
-$13,406
(58.38%↑ Y/Y)
Amortization of deferred
grant reimbursement
-$11,991
(55.85%↑ Y/Y)
Back
Back
Cash Flow
EXOZYMES INC. (EXOZ)
EXOZYMES INC. (EXOZ)
source: myfinsight.com